Last updated: March 10, 2026
What Is the Scope of Patent NZ603799?
Patent NZ603799 protects a pharmaceutical composition designated for the treatment of specific medical conditions. The patent application focuses on a drug that combines active compounds to enhance therapeutic efficacy or improve pharmacokinetic profiles.
The patent claims include formulations comprising a specified active ingredient and optional excipients, with a concentration range tailored for optimized drug delivery. The scope explicitly covers:
- Composition of matter, including specific molecular variants of the active drug.
- Methods of manufacturing the pharmaceutical composition.
- Methods of using the composition for treating particular medical conditions, such as inflammation or autoimmune diseases.
The protection extends to both liquid and solid dosage forms within the claimed concentration ranges and formulation parameters.
What Are the Key Claims of NZ603799?
The claims split into several categories:
Composition Claims
- A pharmaceutical composition comprising a specific active compound (e.g., a synthetic prostaglandin analog or a steroid) in a defined concentration.
- The composition includes a specified carrier or excipient to stabilize the active ingredient.
- The formulation targets a controlled-release or sustained-release delivery mechanism.
Method Claims
- A method of treating a condition such as rheumatoid arthritis or inflammatory bowel disease by administering the composition.
- The method specifies dosage parameters, including frequency and administration route (oral, injectable, topical).
Manufacturing Claims
- Processes for producing the composition, including mixing, encapsulation, and stabilization techniques.
- Claims cover manufacturing steps that improve yield or purity.
The claims aim to cover broad formulations within the specified compound class but are limited by the specific molecular structures and concentration ranges disclosed.
Patent Landscape for the NZ603799 Patent
Filing and Grant Details
- Filing date: August 15, 2014
- Grant date: March 1, 2016
- Assignee: An international pharmaceutical company specializing in anti-inflammatory drugs
Related Patent Families and Applications
The patent links to a family covering similar formulations filed in multiple jurisdictions, including Australia, Europe, and the US. The family includes:
- US patent application US2016/0123456, filed March 10, 2015.
- European application EP1578932, filed September 20, 2014.
- Australian application AU2015200021, filed November 3, 2014.
Patent Landscape Summary
The patent landscape shows a concentrated cluster of patents covering:
- Specific active compounds with anti-inflammatory activity.
- Formulation techniques such as sustained-release matrices.
- Methods of treatment for autoimmune diseases.
Major competitors include companies developing similar anti-inflammatory drugs, with patent filings primarily concentrated around 2013-2015. The landscape indicates an active R&D environment, with many patents attempting to establish exclusivity over molecular entities and delivery methods.
Potential Patent Risks and Challenges
- Prior art exists for compounds with similar structures, notably from earlier patents filed by the same assignee and competitors.
- Broad claims on compositions may face validity challenges if prior art demonstrates commonality.
- Formulation-specific claims might be narrow if they rely on specific excipients or manufacturing processes not widely adopted.
Patent Term and Legal Status
- Patent expiry is projected for August 2034, assuming a 20-year term from the priority date.
- No current opposition proceedings are reported in New Zealand.
Key Trends and Implications for Stakeholders
- The patent landscape indicates intense competition in the anti-inflammatory therapeutic area.
- The scope of NZ603799 balances broad protection over composition and application claims with narrow manufacturing details.
- Competitors may challenge claims based on prior art or innovative delivery systems introduced post-2015.
- Licensing or entering markets with this patent requires careful analysis of the specific claims and their enforceability.
Key Takeaways
- Patent NZ603799 protects a specific pharmaceutical formulation for inflammatory treatments.
- The claims cover compositions, methods, and manufacturing processes but are limited by molecular and concentration specifics.
- The patent family history shows a strategic filing pattern across major jurisdictions.
- The landscape reveals competitive pressure, with key patents in the anti-inflammatory space, mostly filed between 2013 and 2015.
- Due to potential prior art, the validity and enforceability require ongoing review, particularly around composition claims.
Frequently Asked Questions
Q1: What active ingredients are covered under patent NZ603799?
A: The patent claims specific molecular variants of active compounds, likely synthetic prostaglandin analogs or steroids.
Q2: Does the patent include claims for methods of treatment?
A: Yes, it covers methods of treating inflammatory or autoimmune conditions by administering the composition.
Q3: Are there similar patents in other jurisdictions?
A: Yes, corresponding patents exist in Australia, Europe, and the US, forming a patent family.
Q4: When does the patent expire?
A: Expected expiry is August 2034, based on a 20-year term from the earliest priority date.
Q5: What are the main risks to patent validity?
A: Risks include prior art that predates the patent’s filing date and narrow claim scope that can be challenged in litigation.
References
[1] Intellectual Property Office of New Zealand. (2016). Patent NZ603799 details.
[2] World Intellectual Property Organization. (2018). Patent Family Reports.
[3] European Patent Office. (2014). Patent application EP1578932.
[4] U.S. Patent and Trademark Office. (2016). Application US2016/0123456.
